Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $17M | $-21M | $-24M | $-22M | -54.7% | -16.1% | -21.0% |
| 2024 | $20M | $-28M | $-30M | $-20M | -97.0% | 8.2% | 350.0% |
| 2023 | $19M | $-5M | $-7M | $-17M | -21.3% | -29.5% | -65.7% |
| 2022 | $26M | $-18M | $-20M | $-12M | -179.6% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 16.96 |
| Operating Revenue | 16.96 |
| Cost Of Revenue | 13.70 |
| Gross Profit | 3.25 |
| Operating Expense | 28.53 |
| Research And Development | 14.32 |
| Selling General And Administration | 13.92 |
| Total Expenses | 42.24 |
| Operating Income | -25.28 |
| Total Operating Income As Reported | -25.27 |
| EBITDA | -21.47 |
| Normalized EBITDA | -22.21 |
| EBIT | -23.33 |
| Interest Income | 1.86 |
| Interest Expense | 0.38 |
| Net Interest Income | 0.82 |
| Other Non Operating Income Expenses | 0.01 |
| Other Income Expense | 0.75 |
| Interest Income Non Operating | 1.86 |
| Interest Expense Non Operating | 0.38 |
| Net Non Operating Interest Income Expense | 0.82 |
| Pretax Income | -23.71 |
| Tax Provision | 0.17 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0.16 |
| Net Income Continuous Operations | -23.88 |
| Net Income From Continuing And Discontinued Operation | -23.88 |
| Net Income From Continuing Operation Net Minority Interest | -23.88 |
| Net Income | -23.88 |
| Net Income Common Stockholders | -23.88 |
| Net Income Including Noncontrolling Interests | -23.88 |
| Normalized Income | -24.46 |
| Diluted NI Availto Com Stockholders | -23.88 |
| Basic Average Shares | 11.38 |
| Diluted Average Shares | 11.38 |
| Reconciled Depreciation | 1.86 |
| Reconciled Cost Of Revenue | 12.13 |
| Total Unusual Items | 0.74 |
| Total Unusual Items Excluding Goodwill | 0.74 |
| Net Income Discontinuous Operations | - |
| Special Income Charges | - |
| Other Special Charges | - |
| Gain On Sale Of Security | 0.74 |
| Depreciation Amortization Depletion Income Statement | 0.29 |
| Depreciation And Amortization In Income Statement | 0.29 |
| General And Administrative Expense | 10.06 |
| Other Gand A | 3.13 |
| Salaries And Wages | 6.92 |
| Total Other Finance Cost | 0.66 |
| Other Operating Expenses | - |
| Selling And Marketing Expense | 3.87 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MediWound Ltd.this co. | MDWD | $186M | -7.78 | 4.26 | -54.7% | -8.81 |
| Nkarta, Inc. | NKTX | $198M | - | 0.63 | -33.3% | - |
| Anika Therapeutics, Inc. | ANIK | $197M | -18.09 | 1.37 | -7.6% | -31.11 |
| Lucid Diagnostics Inc. | LUCD | $195M | - | 17.79 | -645.1% | - |
| Cartesian Therapeutics, Inc. | RNAC | $192M | -1.48 |
| - |
| - |
| - |
| - |
| - |
| -1.52 |
| 103.2% |
| -0.96 |
| KORU Medical Systems, Inc. | KRMD | $190M | -72.09 | 11.15 | -15.5% | -85.47 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $189M | -1.53 | 0.77 | -50.6% | 0.14 |
| Stereotaxis, Inc. | STXS | $184M | -8.49 | 13.63 | -160.5% | -8.55 |
| Quanterix Corporation | QTRX | $179M | -1.67 | 0.61 | -36.2% | -2.05 |
| Peer Median | - | -5.08 | 1.07 | -34.8% | -5.30 | |